Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 2, 2010

View Archived Issues

Prometheus and AstraZeneca extend U.S. distribution agreement for Entocort EC

PI3K-delta inhibitor XL-499 shows promising preclinical activity

Somatic GNAQ/GNA11 mutations may contribute to development of uveal melanoma

Elara Pharma's new antitumor agent EL-102 inhibits HIF-1-alpha and cellular proliferation

PhaseBio begins phase I/IIa study of Glymera in type 2 diabetes

Phase II data presented on imatinib in diffuse cutaneous systemic sclerosis

Array to initiate clinical development of ARRY-382

Genzyme sells genetic testing business to LabCorp

Watson Pharma launches ella emergency contraceptive in U.S.

Health Canada approves velaglucerase alfa for type I Gaucher's disease

AxoGlia Therapeutics presents new inhibitors of Notch signaling pathway

Mymetics' HIV vaccine shows encouraging preliminary phase I results

Fresenius Medical Care and Galenica form new company

Pronova BioPharma describes new lipid molecules

Symphogen receives milestone payment for antibody therapeutic

NovaBay and FDA discuss clinical development of NVC-422 for impetigo

IRM discovers new prostaglandin E synthase inhibitors

Roche claims new isoquinoline derivatives

Roche divulges new inhibitors of beta-secretase 2

Phase I trial of INK-128 initiated in multiple myeloma

ImmunoGen begins phaseI/II trial of IMGN-901 for SCLC

Medivation and Astellas complete enrollment in phase III MDV-3100 trial

FDA to request further information for Cavatak IND for phase II melanoma trial

Janssen and GE Healthcare to codevelop diagnostic for Alzheimer's disease

Oncolytics Biotech begins enrollment in phase II Reolysin study in ovarian cancer

Study combines structural and functional tests to monitor progression of COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...